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 التهوية غري الباضعة وعالج قنيات األنف ذات التدفق العايل
لألطفال املصابني بالفشل التنفسي احلاد
استعراض عام
خلود �شعيد املخينية و جنوى مرهون الرحبية
abstract: Noninvasive ventilation (NIV) refers to the use of techniques to deliver artificial respiration to the 
lungs without the need for endotracheal intubation. As NIV has proven beneficial in comparison to invasive 
mechanical ventilation, it has become the optimal modality for initial respiratory support among children in 
respiratory distress. High-flow nasal cannulae (HFNC) therapy is a relatively new NIV modality and is used for 
similar indications. This review discusses the usefulness and applications of conventional NIV in comparison to 
HFNC.
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امللخ�ص: التهوية غري البا�شعة ت�شري اإىل ا�شتخدام تقنيات لتوفري التنف�ص ال�شطناعي للرئتني دون احلاجة اىل التهوية امليكانيكية. مبا 
اأن تقنية التهوية غري البا�شعة اأثبتت فائدتها باملقارنة مع التهوية امليكانيكية البا�شعة، فقد اأ�شبحت الطريقة املثلى للدعم التنف�شي 
الأويل لالأطفال الذين يعانون من �شيق التنف�ص. يعترب عالج القنيات الأنفية ذات التدفق العايل من الطرق اجلديدة ن�شبيًا  للتهوية غري 
عالج  مع  باملقارنة  التقليدية  البا�شعة  غري  التهوية  واإ�شتخدامات  فوائد  املراجعة  هذه  تناق�ص  مماثلة.  لتطبيقات  وي�شتخدم  البا�شعة 
القنيات الأنفية ذات التدفق العايل.
الكلمات املفتاحية: التهوية غري البا�شعة؛ قنيات اأنفية؛ تنبيب الرغامى؛ التهوية امليكانيكية؛ الأطفال.
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The use of noninvasive devices in the treatment of acute respiratory distress has inc-reased in paediatric care over the last decade.1 
Noninvasive ventilation (NIV) includes the use of an 
interface to support breathing, thus avoiding invasive 
procedures like endotracheal intubation.2 Techniques 
for NIV include continuous positive airway pressure 
(CPAP), bilevel positive airway pressure (BPAP) and, 
more recently, high-flow nasal cannulae (HFNC).1,3 




Various adult and paediatric studies have demonstrated 
the advantages of conventional NIV modalities, such as 
reducing the need for invasive mechanical ventilation 
and, therefore, its associated complications.2,4–6 In an 
adult randomised controlled trial (RCT), Antonelli 
et al. found that NIV resulted in a reduced risk of 
pneumonia and sinusitis; moreover, pulmonary gas 
exchange resulted in similar effects to invasive mech- 
anical ventilation within the first hour of treatment.2 
Yañez et al. reported similar findings among 50 
children with respiratory failure, in which the NIV 
group demonstrated significant improvement following 
gas exchange within the first hour as well as a 
reduced need for intubation.4 In other studies, NIV 
use has reduced the length of intensive care unit 
(ICU) stay.5,6 Furthermore, NIV has economic advant-
ages over conventional mechanical ventilation, as most 
children undergoing invasive mechanical ventilation 
require ICU admission and additional interventions, 
thereby increasing the overall cost of treatment.7
Over time, NIV has become the first line of treatment 
for paediatric respiratory distress in many countries.1,5,8 
Moreover, in view of the advantages of this modality, its 
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use has been adopted not only in specialised paediatric 
ICUs but also in general emergency departments, 
transport teams and general wards, although trained 
staff and proper equipment are still necessary.9
mechanism of action 
CPAP involves the use of continuous distending pressure 
applied to the airway at a constant level.10,11 On the 
other hand, BPAP delivers two different types of pressure 
during inspiration and expiration, respectively.11 Both 
CPAP and expiratory positive airway pressure during 
BPAP allow for the relief of upper airway obstruction and 
lung recruitment resulting in enhanced gas exchange, 
thereby reducing ventilation-perfusion mismatching 
and improving oxygenation and carbon dioxide (CO2) 
clearance.10,11 In addition, BPAP devices have the option 
of a backup rate to ensure a minimum respiratory 
rate is maintained in cases where respiratory effort is 
inadequate.
Essouri et al. reported the physiological effects of 
NIV in children presenting with acute respiratory failure; 
the study showed that children receiving NIV had signif- 
icantly improved work of breathing (WOB) as well as 
blood gas results and inspiratory muscle effort.12 Add-
itionally, oesophageal and diaphragmatic pressure-time 
products dropped with NIV treatment, while measured 
tidal volume and minute ventilation increased.12
clinical indications and 
applications
For infants and children presenting with acute respiratory 
distress and secondary respiratory failure, NIV is the 
first line of treatment to improve gas exchange, avoid 
invasive ventilation and prevent extubation failure. Ganu 
et al. reported an annual 2.8% increase in NIV use among 
bronchiolitis patients over a nine-year period, with an 
annual 1.9% drop in the rate of invasive ventilation.5 
Both Wolfler et al. and Essouri et al. have reported 
similar declines in the rate of invasive mechanical vent-
ilation corresponding to an increase in NIV use.8,13
Different success rates with NIV use have been 
reported for various clinical diseases. Essouri et al. 
and Abadesso et al. reported overall success rates 
of 77% and 77.5%, respectively, among paediatric patients 
receiving NIV for different causes of respiratory 
distress.13,14 However, children admitted with acute 
respiratory distress syndrome (ARDS) has less 
favourable outcomes compared to those admitted with 
pneumonia, sickle cell disease presenting with acute 
chest syndrome and immunocompromised patients 
presenting with acute respiratory failure.13 In two 
other studies of infants treated for bronchiolitis, the 
NIV success rate was 81–83%.5,15 Children with asthma 
also reportedly respond well to NIV treatment, with 
improvements in WOB and asthma severity scores.16
In addition, NIV is also indicated in the prev-
ention of postextubation respiratory failure, either pro- 
phylactically for children at high risk of extubation 
failure or to treat those with postextubation respiratory 
distress or failure. In a recent study, the NIV success 
rate was higher when utilised prophylactically in comp- 
arison to its use as a rescue treatment.17 In addition, 
NIV resulted in an overall success rate of 85% in 
the postextubation period among children receiving 
treatment after open heart surgery.18 Children with 
underlying malignancies who present with acute resp-
iratory failure are also candidates for NIV. However, 
careful patient selection is required as therapy usually 
fails for cases with a more severe clinical course, signif- 
icant pulmonary disease or haemodynamic instability.19 
The NIV success rate among children with ARDS and 
substantial acute lung injuries is between 30–50%.20 
Therefore, it is highly advised that children with ARDS 
are closely monitored when NIV is initiated so that 
any deterioration in their respiratory state can be 
immediately addressed. Furthermore, NIV is recomm-
ended early during the ARDS disease process in order 
to avoid muscle fatigue from the increase in WOB and 
to improve gas exchange.20 Table 1 provides a summary 
of selected studies investigating NIV use in children.4,8,14,19
interface choice
A wide range of interfaces are available for NIV therapy, 
including helmets, full-face masks, oronasal masks, nasal 
masks and nasal cannulae. For children, the choice 
of interface plays an important role in affecting their 
NIV tolerance. In general, most interfaces are effective 
in reducing WOB and improving gas exchange.21 An 
ideal NIV interface is one that is comfortable, does 
not cause claustrophobia, has minimal leakage and 
results in the least patient-ventilator asynchrony. 
Nasal masks are generally better tolerated and have 
less dead space than other types of interfaces. In 
addition, children are often better able to communicate 
and thus more comfortable. However, the use of 
nasal masks is limited in children due to air leaking 
through the mouth.22,23 In contrast, full-face or 
oronasal masks result in minimal leakage and 
ventilator patient asynchrony, although patients can 
experience intolerance and discomfort.24 Differences in 
leakage, side-effects and asynchrony with different NIV 
interfaces are not well described in the literature. The 
British Thoracic Society recommends having different 
sizes and types of NIV interfaces available to ensure 
treatment success.25 
monitoring and predicting 
responders
Although NIV use is primarily advised for children with 
respiratory distress, it is also recommended to differ-
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entiate those who respond to treatment from non-resp- 
onders so as to avoid delaying intubation, if necessary, 
thus worsening patient outcomes.20 Specific predictors 
of NIV failure include worsening vital signs (e.g. respir-
atory rate and heart rate) following NIV treatment, the 
presence of isolated respiratory disease versus multiple 
organ dysfunction and the oxygen saturation (SpO2)/
fraction of inspired oxygen (FiO2) ratio.
26–30 
The SpO2/FiO2 ratio is used as a clinical indicator 
for hypoxaemia, with a lower ratio indicating greater 
severity.26 Children with more severe disease upon 
admission are at increased risk of NIV failure.27 Phy-
siological parameters before treatment have also been 
linked to treatment failure, with responders showing 
improved respiratory rates, heart rates and blood gas 
results.28 In particular, response to NIV therapy is 
demonstrated by improved respiratory rates one hour 
after treatment, with continued improvement in subse- 
quent hours.29 Likewise, responders’ heart rates have 
shown improvement 2–6 hours following the interv-
ention.30 In contrast, a higher FiO2 requirement and 
lower SpO2/FiO2 ratio within one hour of treatment has 
been associated with treatment failure.26–28,30 Finally, 
children with underlying respiratory disease alone are 
less likely to fail NIV treatment compared to children 
with other comorbidities, such as underlying malig-
nancies.27,29
High-Flow Nasal Cannulae
HFNC therapy delivers a humidified oxygen and gas 
mixture heated to approximately 34 °C, allowing higher 
air flow rates exceeding 2 L/minute.3,31,32 These features 
enable the delivery of air flow equal to or greater than the 
inspiratory flow of a spontaneously breathing patient.31
HFNC also has the ability to generate distending 
pressure.3,31 Over the last decade, the use of HFNC 
has increased among neonates, infants, children and 
adults for various clinical indications.31–33 Long et al. 
showed that, in a paediatric population presenting with 
respiratory failure, HFNC had a success rate of 61% 
when initiated in the emergency department.34 
mechanism of action
HFNC works via different mechanisms to improve oxy- 
genation and ventilation and reduce WOB. Moreover, 
HFNC reduces nasopharyngeal dead space due 
to the effect of the high flow on nasopharyngeal 
oxygen-depleted gas, leading to CO2 clearance.
3 
HFNC improves oxygenation as it provides higher 
FiO2 compared to conventional oxygen therapy. 
Additionally, as the gas flow is humidified and warmed, 
this modality improves lung compliance, reduces 
airway resistance and aids in secretion clearance.3,31
Depending on the patient’s weight, the HFNC flow 
and the size of the nasal cannulae compared to the nares, 
HFNC is associated with the generation of positive 
end-expiratory pressure (PEEP).35 The amount of gen-
erated PEEP is also affected by the degree of leakage 
via the mouth.35,36 An early study of preterm babies 
suggested that HFNC can generate positive distending 
pressure similar to that of CPAP and therefore treat 
apnoea of prematurity.37 In a neonate, a flow rate of 
3–5 L/minute is equivalent to CPAP at 6 cm of water 
(H2O), with effective distending pressure.
35,38 Moreover, 
during HFNC, inspiratory pressure remains positive 
throughout the breathing cycle. Milési et al. measured 
oesophageal pressures at different flow rates, with a 
pharyngeal pressure of 0.2 cm of H2O at 1 L/minute 
increasing to 4 cm of H2O at 6–7 L/minute.
39 Overall, 
Table 1: Summary of selected studies evaluating the use of noninvasive ventilation in children4,8,14,19
Author and 
year of study









BPAP 50 children admitted to 
the PICU with respiratory 
distress
• The rate of intubation in the NIV 











7,100 children admitted to 
the PICU with respiratory 
failure
• The use of NIV increased from 
11.6% in 2006 to 14.3% in 2011 and 
18.2% in 2012







151 children with respiratory 
distress
• The overall NIV success rate was 77.5%





BPAP 239 children admitted to 
the PICU with underlying 
malignancies and presenting 
with respiratory failure
• The overall NIV success rate was 74% 
• Predictors of NIV failure included 
cardiovascular dysfunction and a 
TISS of >40 points
NIV = noninvasive ventilation; RCT = randomised controlled trial; BPAP = bilevel positive airway pressure; PICU = paediatric intensive care unit; 
CPAP = continuous positive airway pressure; TISS = Therapeutic Intervention Scoring System.
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no universal equivalence exists between pressure and 
flow rate; therefore, close monitoring of the patient 
remains a necessity.
clinical indications and 
applications
The use of HFNC has broad indications, including 
different causes of respiratory distress. Overall, HFNC 
is most commonly used among children with bronchiol- 
itis and pneumonia.40 Frat et al. found that the use 
of HFNC in hypoxic respiratory failure reduced the 
intubation rate to 38%, leading to a greater number 
of ventilation-free days in an ICU.41 Roca et al. 
showed that HFNC reduced the need for mechanical 
ventilation among patients with respiratory failure 
post-lung transplant.42 Kawaguchi et al. conducted a 
retrospective study evaluating intubation rates in a 
group of children presenting with respiratory distress.43 
This study showed reduced intubation rates among 
children receiving HFNC in comparison to those who 
did not receive HFNC (38% versus 63%), with more 
ventilator-free days in the former group. However, no 
differences were observed in terms of mortality rate or 
paediatric ICU (PICU) length of stay.43 
In a Cochrane review evaluating the effectiveness 
of HFNC among children with bronchiolitis, a 
single pilot study with 19 participants was identified 
comparing HFNC with oxygen delivery via a headbox; 
however, there was insufficient evidence to determine 
the effectiveness of HFNC for treating bronchiolitis.44 
Nevertheless, a recent multicentre RCT comparing the 
outcomes of infants with bronchiolitis treated with 
low-flow oxygen or HFNC showed that there was a 
reduced need for escalation of care among the 
group receiving HFNC.45 In addition, Schlapbach et 
al. evaluated the safety of HFNC while transporting 
ill children between hospitals.46 The majority of 
these children had respiratory conditions requiring 
admission to a PICU, of which 77% were diagnosed 
with bronchiolitis. Overall, the intubation rate decreased 
from 49% to 35% (P <0.001), with none of the HFNC 
patients requiring intubation, developing pneumoth-
orax or going into cardiac arrest.46 Two other studies 
similarly noted a reduction in intubation rates among 
infants admitted with bronchiolitis following the intro- 
duction of HFNC in PICUs (37% versus 7% and 23% 
versus 9%, respectively).47,48 Various studies investig-
ating HFNC use in children and adults are presented 
in Table 2.41,45,49–52
In Spain, two RCTs involving seven adult ICUs 
were conducted to assess the effect of using HFNC in the 
postextubation period on the incidence of reintubation 
and respiratory failure in high- and low-risk patients, 
respectively.49,50 In the first trial, high-risk patients 
who passed spontaneous breathing trials randomly 
received either HFNC or conventional NIV while, in 
the second trial, low-risk patients randomly received 
either HFNC or conventional oxygen therapy.49,50 
Table 2: Summary of selected studies evaluating the use of high-flow nasal cannulae in children and adults41,45,49–52
Author and year 
of study
Study design and 
period
Patients Clinical results





310 adult patients with 
acute hypoxaemic 
respiratory failure with a 
PaO2/FiO2 ratio of 
<300 mmHg
• The rate of intubation in the HFNC group was 
38% compared to 50% in the NIV group and 47% 
in the standard oxygen therapy group




Infants below 12 months 
with bronchiolitis
• The need to escalate care was higher in the group 
receiving low-flow oxygen therapy compared to 
the HFNC group





604 critically-ill adult 
patients admitted to the 
ICU who were at high 
risk of extubation with 
respiratory failure
• HFNC was not inferior to NIV in preventing 
extubation failure and post-extubation respiratory 
failure among high-risk patients





527 critically-ill adult 
patients admitted to the 
ICU who were at low 
risk of reintubation
• HFNC was superior to conventional oxygen 
therapy in preventing reintubation among low-risk 
patients




49 infants with severe 
bronchiolitis
• When compared to HFNC, CPAP was more 
effective in reducing respiratory distress 
• Overall, 55% of infants being treated with HFNC 
had to switch treatment to CPAP




142 infants admitted to 
PICUs with moderate-
to-severe bronchiolitis
• Nasal CPAP is more effective than HFNC in 
initial supportive treatment for infants with 
moderate-to-severe bronchiolitis
PaO2 = partial pressure of arterial oxygen; FiO2 = fraction of inspired oxygen; HFNC = high-flow nasal cannulae; NIV = noninvasive ventilation; 
RCT = randomised controlled trial; ICU = intensive care unit; CPAP = continuous positive airway pressure; PICUs = paediatric intensive care units.
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No difference was found between the two modalities 
in terms of preventing reintubation or postextubation 
respiratory failure among high-risk patients.49 However, 
in low-risk patients, HFNC was superior to conv-
entional oxygen therapy in reducing the risk of reint-
ubation within a 72-hour period.50
advantages and limitations
For infants, HFNC therapy is well tolerated, therefore 
reducing the need for sedation. Furthermore, the 
humidified oxygen improves secretion clearance.3 Among 
adults, HFNC minimises mouth dryness and is gen-
erally perceived to be more comfortable.53 Spentzas 
et al. assessed the comfort of 46 children with respiratory 
distress at 60–90 minutes and 8–12 hours following 
HFNC therapy and found that comfort significantly 
improved following HFNC use.40 Generally, HFNC use 
has been demonstrated to be safe with few reported 
complications. In 2005, there was an outbreak of 
Ralstonia mannitolilytica infections due to contam-
inated HFNC devices (Vapotherm Inc., Exeter, New 
Hampshire, USA), which were subsequently with-
drawn from the market.54 In addition, three cases 
of serious air leak syndrome have been reported.33 
Nevertheless, the over-all risk of air leak syndrome with 
HFNC is no higher than that of low-flow oxygen.45
monitoring and predicting 
responders
As with NIV, certain clinical features can predict the 
response to HFNC therapy. For example, children with 
improved respiratory distress and heart rates are likely 
to be responders to HFNC therapy.55 Moreover, FiO2 
requirements and illness severity are predictors of 
response to treatment. Accordingly, children with 
high SpO2/FiO2 ratios—indicating milder forms of 
lung injuries—and those with lower respiratory rates 
are likely to respond to therapy.35 Roca et al. conducted a 
four-year multicentre prospective observational cohort 
study to assess possible predictors of HFNC failure, in 
which the respiratory rate oxygenation (ROX) index 
(i.e. the ratio of pulse oximetry/FiO2 to respiratory rate) 
was used to assess therapy success.56 At a cut-off value 
of ≥4.88, the ROX index 12 hours after the initiation 
of HFNC therapy yielded a sensitivity of 70% and 
specificity of 72.4% in predicting successful treatment 
for patients with pneumonia.56
Clinical indicators for HFNC therapy failure 
include a lack of improvement in oxygenation, thoraco- 
abdominal asynchrony and the presence of haemody-
namic and neurological impairment.42,57,58 According 
to Oto et al., a drop in heart or respiratory rate and 
improvement in the mean dyspnoea score 30 minutes 
and 12 hours after the initiation of HFNC are indic-
ative of successful treatment.55 In a cohort of 113 infants 
with bronchiolitis undergoing HFNC therapy, Abboud 
et al. observed that a higher Paediatric Risk of Mortality 
Score—which indicates illness severity upon admission 
to the ICU—as well as an elevated CO2 level before 
treatment were predictors of treatment failure.59 The 
study also emphasised that non-improvement in WOB 
was noted among the non-responders.59
Comparison of Therapies
Early studies have shown that the effectiveness of HFNC 
is similar to CPAP, with comparable effects on WOB, 
oxygenation and gas exchange.37,60 The advantages of 
the HFNC system include the easy setup and increase 
in the child’s comfort.34,40 In general, HFNC therapy is 
safe and associated complications, as described earlier, 
are uncommon. Likewise, NIV treatment is safe, with 
dry eyes, dry mouth, claustrophobia and pressure effects 
on the areas of the face covered by the mask being the 
most common complications.22 
Recently, several studies have assessed clinical out- 
comes among children receiving CPAP and HFNC 
therapy. Pedersen et al. reviewed clinical outcomes 
among a historical cohort of 49 infants admitted with 
severe bronchiolitis and treated with CPAP or HFNC.51 
In both groups, respiratory rate declined with treat-
ment; however, improvements in respiratory distress 
were faster with CPAP treatment. Moreover, in 55% 
of children, the mode of treatment was changed from 
HFNC to CPAP due to an increase in respiratory 
distress.51 Additionally, a multicentre RCT evaluated 
the clinical outcomes of infants presenting with mod- 
erate-to-severe bronchiolitis, comparing CPAP treat-
ment at a PEEP level of 7 cm of H2O to HFNC therapy 
at a rate of 2 L/minute/kg.52 Only 5.7% of the infants 
required intubation, with the rest managed using either 
HFNC or CPAP. Interestingly, 31% of the CPAP group 
failed initial respiratory support compared to 50.7% 
of the HFNC group.52 The most common reason for 
failure in the CPAP group was discomfort, while the 
HFNC group failed due to an increase in respiratory 
distress. In both groups, there was a crossover of 
treatment in cases of failure or intolerance to the initial 
support modality.52 
An observational study by Pilar et al. investigated 
the outcomes of children with asthma who were treated 
with HFNC or NIV.61 The study showed no failure in 
the NIV group, while respiratory support had to be 
changed to NIV among 40% of children in the HFNC 
group, thus showing that CPAP was associated with 
a more rapid improvement in respiratory distress.61 
Collectively speaking, while CPAP and HFNC were 
both associated with improvement in respiratory 
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distress, CPAP was superior in treating children with 
significant respiratory distress. On the other hand, 
HFNC was associated with improved tolerance in 
comparison to NIV.52 Therefore, HFNC can be used 
to treat children presenting with milder or less severe 
forms of respiratory distress and in cases where patient 
discomfort is a concern.
Conclusion
Globally, NIV treatment has become the first line of 
respiratory support for children and is safe and effective 
in the treatment of various causes of respiratory 
distress. However, healthcare practitioners should be 
aware of the various indicators or predictors of NIV 
failure in order to avoid unwanted complications assoc- 
iated with delayed invasive ventilation. HFNC therapy 
is a promising NIV modality of respiratory support 
and is indicated for milder forms of respiratory distress. 
Greater use of NIV may reduce the number of referrals 
to ICUs as well as prevent complications resulting 
from invasive mechanical ventilation.
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